Category: C
Royal Mail 2nd Class / Parcel Force 48
UK to UK :Normally arrives in 2-4 business days.
UK to Ireland :Normally arrives in 4-6 business days
UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going
Please note standered delivery is none trackable , none insured , no responsabily for lose or Damage
----------------------------------------------------------------------------------------------------------------
Royal Mail First Class / Parcel Force 24
UK to UK :Normally arrives in 1-2 business days.
UK to Ireland 3-4 business days
UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going
Please note :Trackable , Royal Mail insured up to £50.
--------------------------------------------------------------------------------------------------------
Parcel Force Express AM Guaranteed before Midday.
UK to UK only . UP to 5KG Max Weight
Arrives next day before 12 noon, requires a signature.
Parcel Forcel Terms & Conditions apply
Important: Parcel Force advise that there are some postcodes where an extended delivery time exists, and may affect the date of delivery or the service is not available.
| Category | POM-VPS |
| Temperature | Ambient |
| MA/VM/EU No: | 42058/4028 |
| Species |
|
| VMD Link | https://www.vmd.defra.gov.uk/ProductInformationDatabase/product/A006636 |
| NOAH Link | https://www.noahcompendium.co.uk/?id=-456822 |
| Dosage | Dosage 0.5 ml/50 kg bodyweight, equivalent to 1.0 mg moxidectin/kg bodyweight, given by a single subcutaneous injection in the ear using an 18 gauge, 25-40 mm hypodermic needle. Determine cattle weight to ensure correct dose rate is used. Administration The 50 ml vial stoppers must not be broached more than 20 times. Shake vigorously before use. To ensure administration of a correct dosage, bodyweight should be determined as accurately as possible; accuracy of the dosing should be checked. The injection should be given subcutaneously in the loose tissues on the dorsal surface of the ear, just distal to the distal edge of the auricular cartilage. The dorsal (outer) surface of the ear should first be cleansed with antiseptic and allowed to briefly air dry. Palpate the edge of the auricular cartilage closest to the head, on the dorsal (hairy) surface of the ear. From this landmark, taking care to avoid blood vessels (artery, vein), the needle should be inserted subcutaneously starting at a point approximately 3 to 3.5 cm distal to this edge (away from the head) and directed towards the base of the ear and the needle advanced to the hub. At this point, gently aspirate the syringe to confirm that the needle is not in a blood vessel. Upon injection, the resulting depot should reside just distal to the edge of the auricular cartilage. Following administration, the needle is withdrawn from the skin as pressure is applied for several seconds with the thumb at the point of insertion. Diagram: Ear injection procedureDescription: h-241The injection site is approximately 3.5 cm (1.5 inches) distal to the distal edge of the ear cartilage.Description: h-242Use one hand to grasp and steady the ear. Inject subcutaneously using an 18 gauge x 1 inch needle.Description: h-243Inject contents. Depot should be just distal to the distal edge of the auricular cartilage. Apply pressure at the point of insertion as the needle is withdrawn from the skin to help seal the opening. Due to the long lasting protection against Dictyocaulus viviparus and the stomach worms, Ostertagia ostertagi and Haemonchus placei, a single treatment with the formulation at turn-out helps control parasitic bronchitis (lungworm) and parasitic gastro-enteritis throughout the grazing season by reducing the build-up of infective larvae on pasture associated with these parasites. For best results the injection should be given to each calf of target weight to be grazed together immediately prior to being turned out to pasture. Animals should be set stocked throughout the grazing season or moved to a pasture which has not been grazed by other cattle earlier in the season. |
| Withdrawals | Do not use in animals less than 100 kg bodyweight or greater than 500 kg. Do not inject the product by the intravascular route. Intravascular injection may result in ataxia, paralysis, convulsions, collapse and death. To prevent any intravascular injection, carefully follow the administration procedure described in the “Dosage and administration” section above. Not to be mixed with other veterinary medicinal products before administration. In order to prevent abscesses, a strict aseptic technique is recommended. CYDECTIN 10% LA for Cattle has been formulated specifically for subcutaneous injection in the dorsal surface of the ear of cattle and must not be given by any other route of administration or to any other species. To avoid possible secondary reactions by the death of Hypoderma larvae in the spine or the oesophagus of animals, it is recommended to administer a product effective against Hypoderma larvae after the end of fly activity and before the larvae reach their resting sites. Consult your veterinary surgeon on the correct timing of this treatment. On rare occasions, immediate or delayed swelling can be observed at the injection site, these swellings may further develop into abscesses (approx. 1% of cases). The frequency of injection site swellings tends to be higher in heavier animals. These side effects generally disappear without treatment, within 14 days after administration, some may persist for up to 5 weeks in a number of animals (<5%) and in very rare occasions longer. On rare occasions, depression and ataxia can be observed after injection. In case of hypersensitivity reactions, symptomatic treatment should be applied. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). Care should be taken to avoid the following practices, because they increase the risk of development of resistance and could ultimately result in ineffective therapy: - Too frequent and repeated use of anthelmintics from the same class, over an extended period of time; - Under-dosing which may be due to underestimation of bodyweight, misadministration of the product, or lack of calibration of the dosing device (If any). Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used. Withdrawal period Meat and offal: 108 days. Milk: Not permitted for use in lactating animals producing milk for human consumption or industrial purposes or within 80 days of expected parturition. The withdrawal period is based solely on a single injection at the ear site of injection. Avoid direct contact with skin and eyes. Operator warnings Avoid direct contact with skin and eyes. Wash hands after use. Do not smoke, drink or eat while handling the product. Take care to avoid self-injection. Advice to Medical Practitioners in case of accidental self-injection: Treat symptomatically. Other precautions regarding impact on the environment Moxidectin fulfils the criteria for a (very) persistent, bioaccumulative and toxic (PBT) substance; therefore, exposure of the environment to moxidectin must be limited to the extent possible. Treatments should be administered only when necessary and should be based on faecal egg counts or evaluation of the risk of infestation at the animal and/or herd level. Like other macrocyclic lactones, moxidectin has the potential to adversely affect non-target organisms: •Faeces containing moxidectin excreted onto pasture by treated animals may temporarily reduce the abundance of dung feeding organisms. Following treatment of cattle with the product, levels of moxidectin that are potentially toxic to dung fly species may be excreted over a period more than 4 weeks and may decrease dung fly abundance during that period. It has been established in laboratory tests that moxidectin may temporarily affect dung beetle reproduction; however, field studies indicate no long-term effects. Nevertheless, in case of repeated treatments with moxidectin (as with products of the same anthelmintic class) it is advisable not to treat animals every time on the same pasture to allow dung fauna populations to recover. •Moxidectin is inherently toxic to aquatic organisms including fish. The product should be used only according to the label instructions. Based on the excretion profile of moxidectin when administered as the injectable formulation, treated animals should not have access to watercourses during the 10 days after treatment. |
